We found that ESR2 mRNA is not abundantly expressed in primary breast cancer, but that higher ESR2 expression is found particularly within ERα-negative breast cancer subtypes and that ESR2-high has a significant association to survival in endocrine-treated patients as well as patients with TNBC. This evidence concerns the gene ESR2 and breast carcinoma.